- Abstract:
-
Inhibition of sclerostin is a therapeutic approach to lowering fracture risk in patients with osteoporosis. However, data from phase 3 randomized controlled trials (RCTs) of romosozumab, a first-in-class monoclonal antibody that inhibits sclerostin, suggest an imbalance of serious cardiovascular events, and regulatory agencies have issued marketing authorizations with warnings of cardiovascular disease. Here, we meta-analyze published and unpublished cardiovascular outcome trial data of romos...
Expand abstract - Publication status:
- Published
- Peer review status:
- Peer reviewed
- Files:
-
- Publisher copy:
- 10.1126/scitranslmed.aay6570
-
Version unsuitable
-
We have not obtained a suitable full-text for a given research output. See this page for more information.
-
Recently completed
-
Sometimes content is held in ORA but is unavailable for a fixed period of time to comply with the policies and wishes of rights holders.
-
Permissions
-
All content made available in ORA should comply with relevant rights, such as copyright. See this page for more information.
-
Clearance
-
Some thesis volumes scanned as part of the digitisation scheme funded by Dr Leonard Polonsky are currently unavailable due to sensitive material or uncleared third-party copyright content. We are attempting to contact authors whose theses are affected.
- Publisher:
- American Association for the Advancement of Science Publisher's website
- Journal:
- Science Translational Medicine Journal website
- Volume:
- 12
- Issue:
- 549
- Article number:
- eaay6570
- Publication date:
- 2020-06-24
- Acceptance date:
- 2020-05-26
- DOI:
- EISSN:
-
1946-6242
- ISSN:
-
1946-6234
- Pubs id:
-
1112307
- Local pid:
- pubs:1112307
- Language:
- English
- Keywords:
- Copyright holder:
- Bovijn et al.
- Copyright date:
- 2020
- Rights statement:
- © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works
- Notes:
- This is the accepted manuscript version of the article. The final version is available from American Association for the Advancement of Science at: https://doi.org/10.1126/scitranslmed.aay6570
Journal article
Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics
Actions
Access Document
Why is the content I wish to access not available via ORA?
Bibliographic data (the information relating to research outputs) and full-text items (e.g. articles, theses, reports, etc.) arrive in ORA from several different sources. Unfortunately we are not able to make available the full-text for every research output.
Please contact the ORA team (
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
Content may be unavailable for the following four reasons
Alternative access to the full-text
You may be able to access the full-text directly from the publisher's website using the 'Publisher Copy' link in the 'Links & Downloads' box from a research output's ORA record page. This method may require an institutional or individual subscription to the journal/resource.
Authors
Funding
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record